anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
An anaesthetic preparation comprises a soluble barbiturate salt and a soluble salt of a b ,b -disubstituted glutarimide of general formula &lt;FORM:0829355/VI/1&gt; wherein R1 and R2 are lower alkyl groups containing up to 6 carbon atoms and which may be joined to form an alicyclic ring, and X is a metal chosen from Group I or II of Mendelief&#39;s Periodic Table.  The barbiturate and glutarimide are present preferably as their salts with alkali metals especially sodium. The glutarimide may be present in amounts of between 10 and 50% by weight of that of the barbiturate.  The preparation may be in the form of a dry powder which gives an injectable solution when, for example, sterile water is added, or it may be in the form of an injectable solution which may also contain propylene glycol and also one or both of dimethyl formamide and diethylacetamide.  The barbiturates used may be &#34;short&#34; or &#34;ultra-short&#34; acting. Examples of barbiturates given are hexabarbitone, thiopentone, and pentobarbitone.  The substituted glutarimides are exemplified by b -ethyl-b -methyl glutarimide.  Up to 53% by weight of the glutarimide salt may be replaced in the preparation by the free imide.
NEW MATERIAL:4-Aminocotinine shown by the formula I. USE:White crystal, compound having 125-126 deg.C melting point, and specific rotary power [alpha]&lt;25&gt;d=-95.2 deg. (c=0.7, MeOH), useful as an improved artificial antigen for nicotine, having pyridine ring, pyrrolidine ring, and optical activity important as an artificial antigen for nicotine. PREPARATION:Cotinine shown by the formula II is oxidized with a preacid such as H2O2, etc. to form cotinine-N-oxide shown by the formula III, which is reacted with conc. sulfuric acid and fuming sulfuric acid to give 4- nitrocotinine-N-oxide shown by the formula IV. This compound is reduced with iron in acetic acid to give 4-aminocotinine shown by the formula V, which is reduced with diborane to give easily the compound shown by the formula I.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a biological information processor capable of reducing labor and time for inputting biological information, and to provide a biological information processing method.  &lt;P&gt;SOLUTION: In one embodiment, a display processing part 104 displays, at the screen of a display device, a graph where the measurement time and measurement value of vital data are respectively made to be X, Y axes. A data processing part 106 determines the measurement time and the measurement value respectively corresponding to the X, Y components of a designation coordinate by a designation operation for designating the coordinate of the display graph with the use of a mouse. In another embodiment, an operation processing part 112 selects one of the measurement times in the trend of the measurement values of the vital data. A server data communication part 110 acquires from a server system the plurality of measurement values at the plurality of measurement times during a period including the selected measurement time. A display processing part 104 displays the acquired measurement values at the screen of the display device. The operation processing part 112 selects one of the displayed measurement values. A data processing part 106 changes the measurement value in the trend at the selected measurement time into the selected measurement value.  &lt;P&gt;COPYRIGHT: (C)2008,JPO&amp;INPIT
&lt;P&gt;PROBLEM TO BE SOLVED: To obtain a composition suitable as an easily usable foamy sterilizing, disinfecting and cleaning agent having sufficiently high frothing property.  &lt;P&gt;SOLUTION: This composition for the foamy sterilizing, disinfecting and cleaning agent contains a nonionic surfactant selected from polyalkylene glycol ethers and polyglycerol fatty acid esters, a sterilizing component and water as essential components. Preferably, the nonionic surfactant has an HLB of ≥10 and is selected from polyglycerol fatty acid esters, and the sterilizing component is selected from hinokitiol, a hinokitiol salt and a hinokitiol complex. The composition is free from lower alcohols, anionic surfactants, amphoteric surfactants and cationic surfactants. The composition is especially suitable as a pump-foam type agent.  &lt;P&gt;COPYRIGHT: (C)2006,JPO&amp;NCIPI
The invention provides a preparation method of assistant hypoglycemic corn-stigma extractive capsules. The active ingredient of the corn stigma extractive capsules is corn-stigma total flavones. A corn-stigma extractive is obtained through extraction by means of an ethyl alcohol organic solvent, and the marking ingredient of the corn-stigma extractive is the total flavones. An optimal process is obtained through an orthogonal experiment, and the content of the corn-stigma total flavones is high. A process for preparing the corn-stigma extractive capsules is optimized. The corn-stigma extractive capsules pass an assistant hypoglycemic function test, and the high-dosage corn-stigma extractive can remarkably inhabit continuous blood glucose rise (p&lt;0.05) of a mouse model suffering from diabetes caused by alloxan. The corn-stigma extractive capsules belong to a newly-developed pure natural assistant hypoglycemic health-care food which is remarkable in hypoglycemic effect, free of toxic and side effects, safe and effective and can be taken for a long time.
Efforts have been made in the past to improve the wellbeing of a person. Various methods involve use of virtual pet character which can interact with the person. But these methods are mainly for entertainment purpose, people get bored quickly. Moreover, the present application doesn&#39;t take into the input of the present state of user. A method and system for improving wellbeing of person using a digital character such as virtual pet has been provided. The system maintains a wellbeing index for both the user and digital character. A set of activities are provided which is performed by the digital character and the user. Further, a response of the user is also captured depending on the current wellbeing index using a set of questionnaire. And a second set of activities are recommended based on the response to further improve the wellbeing index of the person.
The invention discloses a traditional Chinese medicine composition for treating chicken infectious bronchitis and a preparation method thereof, and belongs to the technical field of veterinary traditional Chinese medicine. The traditional Chinese medicine composition is mainly composed of the following traditional Chinese herbals in parts by weight: 200 to 300 parts of ephedra stem, 150 to 300 parts of folium isatidis, 100 to 250 parts of gypsum, 100 to 200 parts of fructus forsythiae, 100 to 200 parts of coptis, 100 to 200 parts of honeysuckle flower, 50 to 150 parts of dandelion, 70 to 150 parts of radix scutellariae, 120 to 150 parts of almond, 100 to 120 parts of dwarf lilyturf tuber, 50 to 150 parts of mulberry bark, 100 to 150 parts of radix scrophulariae, 70 to 100 parts of garden burnet, 10 to 50 parts of licorice, 100 to 150 parts of balloonflower root, and 50 to 150 parts of chrysanthemum. The traditional Chinese herbals mentioned above are compounded according to the principle of &#34;monarch, minister, assistant and guide&#34; in traditional Chinese medicine. The traditional Chinese herbals are co-used to generate the functions of preventing bacteria, inflammation, and viruses, invigorating the stomach, nourishing the spleen, and modulating and strengthening the organism immunity. The traditional Chinese medicine composition is mainly used to prevent and treat chicken infectious bronchitis, and has the advantages of rapid and definite effect. Moreover, the traditional Chinese medicine composition is completely composed of pure traditional Chinese herbals, and has the advantages of low price, safety, no drug residue, and no side or toxic effect on poultry.
The invention relates to a process for the deformation treatment of keratin fibres in which the keratin fibres are exposed to the action of a reactive reducing solution which contains reducing agents to break open the cystine linkages present in the fibres, a rinsing is carried out after the action of this solution, the fibres are exposed to the action of an oxidising agent in order to form cystine linkages again, and another rinsing is carried out where appropriate. Damage to the fibres is effectively prevented according to the invention by rinsing, after the exposure to the reducing solution, with an aqueous solution which has the effect that at no time during the rinsing process is the diameter of the fibres more than 30% larger than at the end of the reduction step. The solutions preferably used for rinsing have an osmotic pressure of more than 4.5 x 10&lt;5&gt; Pa against distilled water at 25 DEG C. The effects for processes of the state of the art and for processes and compositions of the invention are illustrated by Fig. 1 and Fig. 2. &lt;IMAGE&gt;
Disclosed is a compound represented by the Structural Formula (I); Y is a covalent bond, a phenylene group or a substituted or unsubstituted straight chained hydrocarbyl group. In addition, Y, taken together with both &gt;C=Z groups to which it is bonded, is a substituted or unsubstituted aromatic group. Preferably, Y is a covalent bond or -C(RR)-. Rand Rare independently an aryl group or a substituted aryl group, Rand Rare independently -H, an aliphatic group, a substituted aliphatic group, an aryl group or a substituted aryl group. R- Rare independently -H, an aliphatic group, a substituted aliphatic group, an aryl group or a substituted aryl group. Rand Rare each independently -H, an aliphatic or substituted aliphatic group, or Ris -H and Ris a substituted or unsubstituted aryl group, or, Rand R, taken together, are a C2-C6 substituted or unsubstituted alkylene group. Z is =O or =S. Also disclosed are pharmaceutical compositions comprising the compound of the present invention and a pharmaceutically acceptable carrier or diluent. Also disclosed is a method of treating a subject with cancer by administering to the subject a compound of Structural Formula (I) in combination with taxol or an analog of taxol.
&lt;P&gt;PROBLEM TO BE SOLVED: To obtain a thrombogenic inhibitor or a platelet aggregation inhibitor and a functional food usable for prophylaxis of diseases caused by thrombosis.  &lt;P&gt;SOLUTION: The thrombogenic inhibitor or platelet aggregation inhibitor comprises proanthocyanidin and the functional food comprises the drug. Proanthocyanidin derived from grape seeds are preferably used as the proanthocyanidin. A pharmaceutical preparation and the functional food can be used for treatment or prophylaxis of diseases associated with circulatory failure or vascular occlusion due to thrombosis, e.g. cerebrovascular diseases such as cerebral infarction, cerebrovascular dementia or transient cerebral ischemic attack, ischemic heart diseases such as myocardial infarction or angina pectoris or peripheral diseases such as chronic artery occlusion, intermittent claudication, numbness of limbs, hypacusia or pain. Furthermore, the pharmaceutical preparation and functional food can be used for the treatment or prophylaxis of diseases regarded as being associated with the circulatory failure due to the thrombosis as one cause such as so-called senility.  &lt;P&gt;COPYRIGHT: (C)2004,JPO&amp;NCIPI
The present invention concerns methods and compositions of use for treatment of Alzheimer&#39;s Disease (AD). In certain embodiments, the methods concern preparation of phage-display single chain antibody libraries and screening against amyloid-beta (Abeta) protein or peptide. Anti-Abeta antibodies are selected and sequenced. In certain embodiments, synthetic Abeta binding peptides are designed and prepared, using portions of the anti-Abeta antibody sequences. The antibodies and peptides are of use for treatment of AD or for treatment of individuals at risk of developing AD. Compositions comprising anti-Abeta antibodies or Abeta binding peptides are also disclosed.
PURPOSE:A rejection suppressing agent for transplanted piece in order to carry out take of transplanted piece such as skin, organ, etc., consisting of a fat emulsion containing a steroid having immunosuppressive action. CONSTITUTION:A rejection suppressive agent consisting of a fat emulsion containing a steroid (e.g. methylprednisolone) having immunosuppressive action. The preferable form of the fat emulsion is an emulsion comprising an effective amount of steroid, 5-50W/V% soybean oil, a phospholipid having 1-50 weight ratio to 100 soybean oil and a proper amount of water. The emulsion is a drug which has &lt;=1.0mu average particle diameter, is extremely fine and has stable immunosuppressive action. When the drug is administered in order to carry out take of transplanted piece such as skin, organ, etc., much more concentration to immune carrying organ is possible and the drug has long acting activity at the site. Consequently since the immunosuppressive agent exhibits improved suppressive action on delayed hypersensitivity reaction with a small amount of administration and side effects caused by a large amount of administration can be avoided.
PURPOSE:To eliminate the stimuli to the skin and to obviate the degradation in tacky adhesiveness even after long-term use by forming an adhesive agent layer essentially consisting of a copolymer consisting of specific ratios of the alkyl ester monomer of acrylic acid or methacrylic acid, alkoxyl-contg. ethylenic unsatd. monomer and carboxyl-contg. ethylenic unsatd. monomer. CONSTITUTION:The pressure-sensitive adhesive agent layer 2 of the patch material formed by providing the lay 2 on one surface of a base material film 1 is essentially composed of the copolymer consisting of 40 to 80wt.% the alkyl ester monomer of the acrylic acid or methacrylic acid, 10 to 50wt.% alkoxyl- contg. ethylenic unsatd. monomer and 1 to 10wt.% carboxyl group-contg. ethylenic unsatd. monomer. The glass transition point of the copolymer is &lt;=250 deg.K and the gel fraction of the copolymer after drying is &gt;=25%. Materials, such as polyether urethane, polyester urethane, polyether polyamide block polymer, and polyacrylate, which have good water vapor transmittability, are adequately used as the base material film 1.
This invention relates to a method for the biochemical treatment of persistent pain disorders by inhibiting the biochemical mediators of inflammation in a subject comprising administering to said subject any one of several combinations of components that are inhibitors of biochemical mediators of inflammation. Said process for biochemical treatment of persistent pain disorders is based on Sota Omoigui&#39;s Law, which states: ‘The origin of all pain is inflammation and the inflammatory response’. Sota Omoigui&#39;s Law of Pain unifies all pain syndromes as sharing a common origin of inflammation and the inflammatory response. The various biochemical mediators of inflammation are present in differing amounts in all pain syndromes and are responsible for the pain experience. Classification and treatment of pain syndromes should depend on the complex inflammatory profile. A variety of mediators are generated by tissue injury and inflammation. These include substances produced by damaged tissue, substances of vascular origin as well as substances released by nerve fibers themselves, sympathetic fibers and various immune cells. Biochemical mediators of inflammation that are targeted for inhibition include but are not limited to: prostaglandin, nitric oxide, tumor necrosis factor alpha, interleukin 1-alpha, interleukin 1-beta, interleukin-4, Interleukin-6 and interleukin-8, histamine and serotonin, substance P, Matrix Metallo-Proteinase, calcitonin gene-related peptide, vasoactive intestinal peptide as well as the potent inflammatory mediator peptide proteins neurokinin A, bradykinin, kallidin and T-kinin.
Vaccines and toxoids are prepared by digesting a pathogenic organism with a proteolytic enzyme, e.g. pepsin, and thereafter oxidizing with a mild acid, e.g. acetic acid and a nitrite, e.g. sodium nitrite, and heating for about 6-28 hours at about 56-64 DEG  C.  If a toxoid is to be produced, the product from this step is subjected to ultrasonic waves (e.g. 800 kc/sec.) to disrupt the cells but the disruption step is omitted if a vaccine is to be produced.  In either case, the product is then placed in contact with a mixture of anionic and cationic air-exchange resins, e.g. &#34;Amberlite&#34; (Registered Trade Mark) IR-120 and IRA-410 for about three weeks and thereafter removed therefrom, e.g. by decantation. By the process of the invention, toxoids may be produced from organisms of the genus Brucella, e.g. Brucella abortus, melitensis and ruis, from streptococci, e.g. Streptococcus hemolyticus and from Escherichia coli.  Vaccines may be prepared from pneumococci, Pseudomonas aeruginosa, the tubercle bacillus, acne bacillus, poliomyelitis virus and an unnamed mycobacterium isolated consistently from animal and human cancer tissue.  It is stated that the modified vaccines and toxoids produced are unchanged in the specificity of their antigenic properties but that their anaphylactogenic properties are diminished and their capacity for promoting antibody formation in vivo are preserved and enhanced.  Specifications 577,707 and 679,850 are referred to.
A system for remotely reviewing medical data allows medical data to be transmitted over a vulnerable network to a physician&#39;s mobile device. The system includes a console, a data server and mobile devices. The system may include medical imaging equipment, medical records databases, and other sensors. Medical data is routed through the console to the data server to reach the mobile device via a wireless network. Patient&#39;s medical file may be separated into a demographics layer and a data layer, and separately encrypted using different encryption keys for the demographic layer and the data layer. Servers in the communication and processing system are provided with a decryption key for the layer processed by such server. Physicians may transmit comments to the requestor through the same system. A resident messaging system may notify users of messages or data awaiting review along with the urgency of the required review are also described.
PURPOSE:To obtain a bathing agent composition, containing inorganic salts combined with a water-soluble silk trituration with Glauber&#39;s salt and water-insoluble porous particles, having heat retaining effects and excellent in preventing effects on drying up of the skin without any stickiness. CONSTITUTION:This.bathing agent composition contains inorganic salts (sodium hydrogencarbonate, sodium sulfate or sodium chloride is especially preferred), a water- soluble silk trituration with Glauber&#39;s salt and water-insoluble porous particles. The water-soluble silk trituration with the Glauber&#39;s salt is prepared by converting sodium sulfate into an anhydride, dissolving the anhydrous sodium sulfate at &lt;20% (g/ml) concentration in an aqueous solution of silk, freeze-drying the resultant solution and triturating the silk with anhydrous sodium sulfate in the form of a crystal (a eutectic) in a homogeneous state. Anhydrous silicic acid, calcium silicate, synthetic aluminum silicate, etc., are cited as the water-insoluble porous particles and the average particle diameter thereof is preferably &gt;=100mum. The volume of oil absorption is preferably &gt;=70ml/100g. The resultant composition is capable of synergistically manifesting preventing effects on drying up of the skin after bathing and improving the moistness of the skin without getting the turbidity or floating, foreign materials after feed thereof into a bath.
PROBLEM TO BE SOLVED: To obtain a new polynucleotide having a base sequence highly identical with a base sequence encoding EBI 3 polypeptide having a specific amino acid sequence and useful for treatment and diagnosis of e.g. infectious diseases, cancer, asthma, hypertension, osteoporosis, cardiac infarction and nervous impairment. SOLUTION: This polynucleotide is a new polynucleotide comprising a polynucleotide at least 95% identical, over the whole length, with a nucleotide sequence encoding EBI 3 of the formula or a nucleotide sequence encoding a polypeptide having the activity of EBI 3 polypeptide or a complementary nucleotide sequence to these nucleotides. EBI polypeptide and polynucleotide is useful for e.g. treatment and diagnosis of infectious diseases, pain, cancer, cibophobia, hyperphagia, asthma, Parkinson&#39;s disease, acute cardiac insufficiency, hypotension, hypertenstion, ischuria, osteoporosis, angina pectosis, ulcer, allergy, benign prostatomegaly, psychiatric and nervous impairments. This polynucleotide is obtained from a natural source, e.g. genome DNA library.
NEW MATERIAL:The hepatic cell proliferation factor having the following properties. Molecular weight, 20,000; free from the characteristics of polysaccharides and glycoproteins; free from species specificity to animal; high thermal stability; exhibits similar culturing effect as bovine-originated fetus serum, quasi-fetus serum or calf serum in the culture of other tissue cells). USE:Agent for promoting hepatic function. PREPARATION:The epithelial mucous tissue of the intestine of a warm-blooded animal (e.g. rat, mouse, chicken, etc.) is homogenized in a salt solution free from Ca and preferably Mg (e.g. Tyrode&#39;s solution) at 0-2 deg.C, and the supernatant liquid is separated from the homogenate by centrifugal separation, etc. The supernatant liquid is dialyzed with the above salt solution to remove the low-molecular weight components, and the obtained fraction is subjected to the gel-filtration and the ion-exchange chromatography to obtain the objective hepatic cell proliferation factor.
The invention relates to self-assembled nanofibres of chitosan and bioactive compounds, which can be used as nutraceuticals or drugs. The bioactive compounds suitable for the nanofibres of the invention are molecules of a low molecular size with acid or lactone groups, aromatic rings and hydroxyls, such as small polyphenols and mixtures thereof. The nanofibres of the invention are absorbed, without degradation, at the level of the small intestine, containing and protecting the bioactive compounds until they reach the various target organs. The nanofibres also cross the blood-brain barrier, allowing the compounds to reach the brain where they act as a controlled release system. If the bioactive compounds are neuroprotectors, such as antioxidants, the nanofibres of the invention can be used to treat or prevent neurodegenerative diseases such as Alzheimer&#39;s disease, Parkinson&#39;s disease, Huntington&#39;s disease and amyotrophic lateral sclerosis (ALS), as well as she strokes and other diseases related to aging or associated with oxidative stress. The invention also relates to the method for obtaining the nanofibres, which comprises mixing chitosan with the bioactive compounds and allowing self-assembly. The invention further relates to the dosage form containing the nanofibres of the invention, particularly for oral administration, such as tablets, coated tablets, powders, capsules, syrups, or others.